In­tel­lia’s sec­ond CRISPR ther­a­py re­duces swelling at­tacks by 95% in hered­i­tary an­gioede­ma

An ex­per­i­men­tal CRISPR ther­a­py has dra­mat­i­cal­ly low­ered lev­els of an in­flam­ma­tion-pro­mot­ing pro­tein and re­duced bouts of harm­ful swelling by 95% in pa­tients with an in­her­it­ed con­di­tion, In­tel­lia Ther­a­peu­tics an­nounced Sun­day at a med­ical con­fer­ence in Ger­many.

A Phase I clin­i­cal tri­al test­ed three dose lev­els of a gene edit­ing ther­a­py in 10 pa­tients with hered­i­tary an­gioede­ma, a rare, ge­net­ic dis­ease that leaves peo­ple prone to sud­den in­flam­ma­tion and swelling. The at­tacks can be dis­fig­ur­ing when be­neath the skin, painful when they oc­cur in the gut, and dead­ly when they block breath­ing in the air­ways.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER